Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 18, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on September 14, 2006:
- Previous Holdings: 17,381,351 Ordinary Share ADRs
- New Holdings: 17,356,021 Ordinary Share ADRs
- Net Change: Decrease of 25,330 ADRs
- Average Price: $55.08
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The Plan is a discretionary fund for employees and former employees; consequently, Directors Dr. J P Garnier and Dr. M M Slaoui are noted as potentially interested in the shares held in the fund.
Investor Verification Points
- Verify the impact of the 25,330 ADR reduction on the total beneficial ownership of the Plan.
- Confirm the specific nature of the "fund movement" that triggered the change in share count.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance context.